TSG11
MCID: TMR016
MIFTS: 28

Tumor Suppressor Gene on Chromosome 11 (TSG11)

Categories: Cancer diseases, Respiratory diseases

Aliases & Classifications for Tumor Suppressor Gene on Chromosome 11

MalaCards integrated aliases for Tumor Suppressor Gene on Chromosome 11:

Name: Tumor Suppressor Gene on Chromosome 11 57 13 70
Nonsmall Cell Lung Cancer Suppressor 57
Non-Small Cell Lung Carcinoma 70
Nonsmall Cell Lung Cancer 57
Tsg11 57

Classifications:



External Ids:

OMIM® 57 603040
UMLS 70 C0007131 C1864232

Summaries for Tumor Suppressor Gene on Chromosome 11

MalaCards based summary : Tumor Suppressor Gene on Chromosome 11, also known as nonsmall cell lung cancer suppressor, is related to lung cancer and neutropenia. An important gene associated with Tumor Suppressor Gene on Chromosome 11 is TSG11 (Tumor Suppressor Gene On Chromosome 11). The drugs Vinorelbine and Zoledronic Acid have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and colon.

More information from OMIM: 603040

Related Diseases for Tumor Suppressor Gene on Chromosome 11

Diseases related to Tumor Suppressor Gene on Chromosome 11 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 123)
# Related Disease Score Top Affiliating Genes
1 lung cancer 12.0
2 neutropenia 10.8
3 lung cancer susceptibility 3 10.7
4 esophagitis 10.7
5 large cell carcinoma 10.7
6 exanthem 10.6
7 adenocarcinoma 10.6
8 lung disease 10.6
9 mucositis 10.5
10 thrombocytopenia 10.5
11 interstitial lung disease 10.5
12 virus-associated trichodysplasia spinulosa 10.5
13 squamous cell carcinoma 10.5
14 bronchiolo-alveolar adenocarcinoma 10.5
15 alopecia 10.4
16 retinoblastoma 10.4
17 proteinuria, chronic benign 10.4
18 lymphoma 10.4
19 constipation 10.4
20 peripheral nervous system disease 10.4
21 lymph node disease 10.4
22 xeroderma pigmentosum, variant type 10.3
23 lung cancer susceptibility 1 10.3
24 diarrhea 10.3
25 pneumothorax 10.3
26 glioblastoma 10.3
27 pulmonary fibrosis 10.3
28 lung squamous cell carcinoma 10.3
29 neuropathy 10.3
30 stomatitis 10.3
31 granulocytopenia 10.3
32 dysphagia 10.3
33 hypoxia 10.3
34 bladder cancer 10.2
35 thrombophilia due to thrombin defect 10.2
36 ataxia-telangiectasia 10.2
37 thrombocytopenia 3 10.2
38 ataxia and polyneuropathy, adult-onset 10.2
39 pulmonary disease, chronic obstructive 10.2
40 mycobacterium tuberculosis 1 10.2
41 pulmonary adenocarcinoma in situ 10.2
42 rapidly involuting congenital hemangioma 10.2
43 respiratory failure 10.2
44 adult respiratory distress syndrome 10.2
45 telangiectasis 10.2
46 melanoma 10.2
47 pulmonary coin lesion 10.2
48 lymphopenia 10.2
49 severe combined immunodeficiency 10.2
50 acne 10.2

Graphical network of the top 20 diseases related to Tumor Suppressor Gene on Chromosome 11:



Diseases related to Tumor Suppressor Gene on Chromosome 11

Symptoms & Phenotypes for Tumor Suppressor Gene on Chromosome 11

Clinical features from OMIM®:

603040 (Updated 05-Apr-2021)

Drugs & Therapeutics for Tumor Suppressor Gene on Chromosome 11

Drugs for Tumor Suppressor Gene on Chromosome 11 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 174)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vinorelbine Approved, Investigational Phase 2, Phase 3 71486-22-1 60780 44424639
2
Zoledronic Acid Approved Phase 3 118072-93-8 68740
3
Ifosfamide Approved Phase 3 3778-73-2 3690
4
Ethanol Approved Phase 2, Phase 3 64-17-5 702
5
Disulfiram Approved Phase 2, Phase 3 97-77-8 3117
6
tannic acid Approved Phase 3 1401-55-4
7
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
8
Osimertinib Approved Phase 3 1421373-65-0 71496458
9
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
10
Methylcobalamin Approved, Investigational Phase 3 13422-55-4
11
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
12
Hydroxocobalamin Approved Phase 3 13422-51-0 11953898 15589840
13
Pembrolizumab Approved Phase 3 1374853-91-4
14
afatinib Approved Phase 2, Phase 3 850140-72-6, 439081-18-2 10184653
15
Cetuximab Approved Phase 2, Phase 3 205923-56-4 56842117 2333
16
Ipilimumab Approved Phase 3 477202-00-9
17
Nicotinamide Approved, Investigational Phase 2, Phase 3 98-92-0 936
18
Paclitaxel Approved, Vet_approved Phase 2, Phase 3 33069-62-4 36314
19
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
20
Cyanocobalamin Approved, Nutraceutical Phase 3 68-19-9 44176380
21
Niacin Approved, Investigational, Nutraceutical Phase 2, Phase 3 59-67-6 938
22
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
23
Cobalamin Experimental Phase 3 13408-78-1 6857388
24 taxane Phase 3
25 Alkylating Agents Phase 3
26 Mitomycins Phase 3
27
Isophosphamide mustard Phase 3 100427
28 Anti-Inflammatory Agents Phase 3
29 Gastrointestinal Agents Phase 3
30 Nutrients Phase 3
31 Micronutrients Phase 3
32 Trace Elements Phase 3
33 Vitamins Phase 3
34 Hormone Antagonists Phase 3
35 glucocorticoids Phase 3
36 Antiemetics Phase 3
37 Hormones Phase 3
38 Antineoplastic Agents, Hormonal Phase 3
39 Vitamin B12 Phase 3
40 Vitamin B 12 Phase 3
41 Vasodilator Agents Phase 2, Phase 3
42 Lipid Regulating Agents Phase 2, Phase 3
43 Vitamin B3 Phase 2, Phase 3
44 Nicotinic Acids Phase 2, Phase 3
45 Hypolipidemic Agents Phase 2, Phase 3
46 Albumin-Bound Paclitaxel Phase 2, Phase 3
47
Erlotinib Hydrochloride Phase 3 183319-69-9 176871
48 Protein Kinase Inhibitors Phase 3
49 Anesthetics Phase 3
50 Antibiotics, Antitubercular Phase 3

Interventional clinical trials:

(show top 50) (show all 286)
# Name Status NCT ID Phase Drugs
1 A Prospective, Multicenter, Phase-IV Clinical Trial to Assess Safety of Osimertinib in Indian Adult Patients With Metastatic Epidermal Growth Factor Receptor (EGFR) T790M Mutation-positive Non-small Cell Lung Cancer (NSCLC). Completed NCT03853551 Phase 4 Osimertinib
2 A Phase IV, Multicenter, Non-randomized, Open-labeled Study to Evaluate the Efficacy of Gefitinib (IRESSA®) as a Second-line Therapy in NSCLC Patients Completed NCT00608868 Phase 4 Gefitinib
3 Pembrolizumab for Metastatic Non-small Cell Lung Cancer (NSCLC) Patients Expressing PD-L1 Who Have Their Own Patient-derived Xenograft (PDX): Comparative Study of Clinical Response and In-vivo Antitumor Response Using Their Humanized CD34 PDX (Hu-CD34 PDX) Recruiting NCT03134456 Phase 4 Pembrolizumab Injection
4 A Randomized, Phase III Trial of Prophylactic Cranial Irradiation (PCI) in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Are Effective on Erlotinib or Gefitinib(RT1001) Unknown status NCT01158170 Phase 3 Erlotinib /Gefitinib
5 Efficacy, Safety & Immunogenicity Study of CBT124 & EU-sourced Avastin® in Combination With Carboplatin and Paclitaxel in First-line Treatment in (NSCLC) Unknown status NCT02879097 Phase 3 Carboplatin;Paclitaxel
6 Randomized Phase III Trial of Stereotactic Radiosurgery (SRS) Versus Observation for Patients With Asymptomatic Cerebral Oligo-metastases in Non-small Cell Lung Cancer (NSCLC) Unknown status NCT01301560 Phase 3
7 Optimization of Treatment of Advanced Nonsmall Cell Lung Cancer Using Radiotherapy and Chemotherapy Completed NCT00864331 Phase 3 Chemotherapy
8 Randomized Controlled Trial to Evaluate Standard Thoracic Radiotherapy With or Without Concurrent Daily Low-dose Carboplatine in Elderly Patients With Locally Advanced Non-small Cell Lung Cancer (JCOG0301, NCSLC-Elderly-CBDCA-RT Phase III) Completed NCT00132665 Phase 3 B: CBDCA and Radiotherapy
9 Non-small Cell Lung Cancer Study US75 (Z-PACT) Completed NCT00086268 Phase 3 zoledronic acid;Taxotere;Carboplatin
10 A Phase III Study to Assess the Efficacy of ZD6474 (ZACTIMA™) Plus Best Supportive Care Versus Best Supportive Care in Patients With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer After Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Completed NCT00404924 Phase 3 ZD6474 (vandetanib)
11 Phase III Trial of Single-Agent Pemetrexed (Alimta®) Versus the Combination of Carboplatin and Pemetrexed in Patients With Advanced Non-small-cell Lung Cancer and Performance Status of 2 Completed NCT01836575 Phase 3 Pemetrexed;Carboplatin
12 The Impact of Positron Emission Tomography (PET) Imaging in Staging Potentially Surgically Resectable Non-small Cell Lung Cancers: A Prospective Multicentre Randomized Clinical Trial Completed NCT00136890 Phase 3
13 The Impact of Positron Emission Tomography (PET) Imaging in Stage III Non-small Cell Lung Cancer: A Prospective Randomized Clinical Trial (PET START Trial) Completed NCT00136864 Phase 3
14 A Randomized Multicenter Phase III Study of Taxane/Carboplatin/Cetuximab Versus Taxane/Carboplatin as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer Completed NCT00112294 Phase 3 Paclitaxel (Taxane);Docetaxel (Taxane);Carboplatin;Cetuximab
15 A Randomized Phase 3 Trial of ALIMTA and Cisplatin Versus GEMZAR and Cisplatin in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Completed NCT00087711 Phase 3 pemetrexed;gemcitabine;cisplatin
16 Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer. Sequential Single-Agent vs. Double-Agent vs. Triple-Agent Therapy. Completed NCT00148395 Phase 3 Gemcitabine;Navelbine;Carboplatin;Cisplatin;Mitomycin;Ifosfamide
17 Phase 3 Randomized Study of TLK286 (Telcyta) Versus Gefitinib (Iressa) as Third-Line Therapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Completed NCT00080340 Phase 3 TLK286 (Telcyta) HCl for Injection;gefitinib (Iressa)
18 A Randomized, Open-Label, Parallel Group, International, Multicenter, Phase III Study of Oral ZD1839 (IRESSA®) Versus Intravenous Docetaxel (TAXOTERE®) in Patients With Locally Advanced or Metastatic Recurrent Non-Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Completed NCT00076388 Phase 3 Gefitinib;Docetaxel
19 A Randomized, Phase III Trial of ABI-007 and Carboplatin Compared With Taxol and Carboplatin as First-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Completed NCT00540514 Phase 3 Albumin-bound paclitaxel;Paclitaxel;Carboplatin
20 A Randomized Double-Blind, Placebo-Controlled, Multicenter Study of CI-994 Capsules Plus Gemcitabine Infusion Versus Placebo Capsules Plus Gemcitabine Infusion as Second-Line Treatment of Patients With Advanced Nonsmall Cell Lung Cancer Completed NCT00005093 Phase 3 gemcitabine hydrochloride;tacedinaline
21 A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors Completed NCT00373425 Phase 3 Erlotinib;Placebo
22 A Prospective Study of the Prognostic Significance of Occult Metastases in the Patient With Resectable Non-Small Cell Lung Carcinoma Completed NCT00003901 Phase 3
23 Randomized Phase 2 Trial of Treatment of Advanced Non Small Cell Lung Carcinoma With/Without Disulfiram and Cisplatin Navelbine Completed NCT00312819 Phase 2, Phase 3 chemotherapy +/- disulfiram
24 LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure Recruiting NCT02973789 Phase 3 Immune checkpoint inhibitors or docetaxel
25 A Randomized, Double-Blind, Phase III Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-189) Active, not recruiting NCT03950674 Phase 3 Cisplatin;Carboplatin;Pemetrexed;Dexamethasone 4 mg;Saline solution
26 A Phase III Randomized, Open-Label, Multi-Center Study of Durvalumab (MEDI4736) Versus Standard of Care (SoC) Platinum-Based Chemotherapy as First Line Treatment in Patients With PD-L1-High Expression Advanced Non Small-Cell Lung Cancer Active, not recruiting NCT03003962 Phase 3 Durvalumab (MEDI4736);Paclitaxel + carboplatin;Gemcitabine + cisplatin;Gemcitabine + carboplatin;Pemetrexed + cisplatin;Pemetrexed + carboplatin
27 A Phase III, Double-blind, Randomized, Placebo-controlled Multi-centre, Study to Assess the Efficacy and Safety of AZD9291 Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA). Active, not recruiting NCT02511106 Phase 3 AZD9291 80 mg/40 mg;Placebo AZD9291 80 mg/40 mg;Open-label AZD9291 80 mg/40 mg
28 A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC) Active, not recruiting NCT02542293 Phase 3 Paclitaxel + carboplatin;Gemcitabine + cisplatin;Gemcitabine + carboplatin;Pemetrexed + cisplatin;Pemetrexed + carboplatin
29 Open-Label, Randomized Trial of Nivolumab (BMS-936558) Plus Pemetrexed/Platinum or Nivolumab Plus Ipilimumab (BMS-734016) vs Pemetrexed Plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor Therapy Active, not recruiting NCT02864251 Phase 3 Pemetrexed;Cisplatin;Carboplatin
30 Randomized Double-blinded Comparative Trial to Study the Add-on Activity of Combination Treatment of Nicotinamide on Progression Free Survival for EGFR Mutated Lung Cancer Terminal Stage Patients Being Treated With Gefitinib or Erlotinib Active, not recruiting NCT02416739 Phase 2, Phase 3 Nicotinamide
31 A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC) Active, not recruiting NCT02438722 Phase 2, Phase 3 Afatinib Dimaleate
32 A Randomized Open-Label Phase III Trial of MK-3475 Versus Platinum Based Chemotherapy in 1L Subjects With PD-L1 Strong Metastatic Non-Small Cell Lung Cancer Active, not recruiting NCT02142738 Phase 3 Pembrolizumab;Paclitaxel;Carboplatin;Pemetrexed;Cisplatin;Gemcitabine
33 A Randomized, Double-Blind, Phase III Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-189) Active, not recruiting NCT02578680 Phase 3 Cisplatin;Carboplatin;Pemetrexed;Dexamethasone 4 mg;Saline solution
34 A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC) (MYSTIC) Active, not recruiting NCT02453282 Phase 3 Paclitaxel + Carboplatin;Gemcitabine + Cisplatin;Gemcitabine + Carboplatin;Pemetrexed + Cisplatin;Pemetrexed + Carboplatin
35 Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for EGFR Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection: A Multicenter, Randomized Controlled, Open-label Clinical Study Not yet recruiting NCT04762459 Phase 3 Almonertinib;Pemetrexed;Cisplatin
36 Prophylactic Cranial Irradiation (PCI) Versus no PCI in Non Small Cell Lung Cancer After a Response to Chemotherapy:A Multi-center Randomized Phase ⅢTrial Terminated NCT00745797 Phase 3
37 A Phase III, Double-Blind, Randomised Study Comparing ZD1839 (IressaTM) Versus Placebo As Maintenance Therapy In Subjects With Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) After Combined Modality Therapy Terminated NCT00234468 Phase 3 Iressa (Gefitinib)
38 Randomized Trial of Epoetin Alfa in Patients With Advanced Non-Small Cell Carcinoma of the Lung (EPO-CAN-20) Terminated NCT00310232 Phase 3 Epoetin Alfa
39 A Phase III Randomised Study Comparing Concomitant Radiochemotherapy With Cisplatin and Docetaxel as Induction Versus Consolidation Treatment in Patients With Locally Advanced Unresectable Non-small Cell Lung Cancer. Terminated NCT00633568 Phase 3 Concomitant Radiochemotherapy - Radiotherapy 66 Gy, Cisplatin, and Docetaxel;Concomitant Chemoradiotherapy - Radiotherapy 66 Gy, Cisplatin, and Docetaxel
40 MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib Terminated NCT00738881 Phase 3 Erlotinib Hydrochloride;Pemetrexed Disodium
41 A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) Terminated NCT01383148 Phase 2, Phase 3 placebo
42 Clinical Trial on the Prevention of Thrombocytopenia After First-line Chemotherapy With GC/GP Regimens for Non-small-cell Lung Carcinoma Using Recombinant Human Thrombopoietin (rhTPO) Terminated NCT01319669 Phase 2, Phase 3 recombinant human thrombopoietin
43 A Phase IIIb Randomized, Double-Blind Study Comparing Maintenance ZD1839 (IRESSA®) or Placebo Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Withdrawn NCT00090675 Phase 3 ZD1839
44 Concurrent Helical Tomotherapy With Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC): a Phase I/II Trial of Radiation Dose Escalation and Fixed Dose Chemotherapy. Unknown status NCT00379717 Phase 1, Phase 2 Cisplatinum;Docetaxel
45 Phase II Protocol for Primary Fractionated Stereotactic Body Radiation Therapy for Stage T1 - T3N0 Non Small Cell Lung Carcinoma. Unknown status NCT00727350 Phase 2
46 Phase II Protocol for Risk-adapted Stereotactic Body Radio Therapy for Stage T1-T3N0 Non-Small Cell Lung Carcinoma Unknown status NCT02224547 Phase 2
47 Phase I/II Study of Vorinostat and Gefitinib in Relapsed/ or Refractory Patients With Advanced Non-small Cell Carcinoma (NSCLC) Unknown status NCT01027676 Phase 1, Phase 2 Study treatment
48 Preoperative Chemoradiotherapy vs. Chemotherapy Alone in Nonsmall Cell Lung Cancer (NSCLC) Patients With Mediastinal Lymph Node Metastases (Stage IIIA, N2): A Randomized Prospective Phase II Trial Unknown status NCT01187290 Phase 2
49 A Phase II Study of Docetaxel and Vinorelbine in Advanced Non-Small Cell Lung Carcinoma Unknown status NCT00006215 Phase 2 docetaxel;vinorelbine tartrate
50 Positron Emission Tomography Pre- and Post-treatment Assessment For Locally Advanced Non-Small Cell Lung Carcinoma Unknown status NCT00083083 Phase 2 carboplatin;cisplatin;docetaxel;etoposide;paclitaxel;vinblastine sulfate;vinorelbine tartrate

Search NIH Clinical Center for Tumor Suppressor Gene on Chromosome 11

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Afatinib
afatinib dimaleate
ceritinib
crizotinib
docetaxel
erlotinib
gefitinib
hydroxyurea
irinotecan
Irinotecan hydrochloride
pembrolizumab
Topotecan
Topotecan Hydrochloride
trametinib
vinorelbine
Vinorelbine tartrate

Genetic Tests for Tumor Suppressor Gene on Chromosome 11

Anatomical Context for Tumor Suppressor Gene on Chromosome 11

MalaCards organs/tissues related to Tumor Suppressor Gene on Chromosome 11:

40
Lung, Brain, Colon, Lymph Node, Skeletal Muscle, Liver, Prostate

Publications for Tumor Suppressor Gene on Chromosome 11

Articles related to Tumor Suppressor Gene on Chromosome 11:

(show all 17)
# Title Authors PMID Year
1
Localization of tumor suppressor activity important in nonsmall cell lung carcinoma on chromosome 11q. 57
9653156 1998
2
Allelic losses in human chromosome 11 in lung cancers. 57
7541642 1995
3
Suppression of tumorigenicity of A549 lung adenocarcinoma cells by human chromosomes 3 and 11 introduced via microcell-mediated chromosome transfer. 57
8098218 1993
4
Unexpected Findings in a Child with Atypical Hemolytic Uremic Syndrome: An Example of How Genomics Is Changing the Clinical Diagnostic Paradigm. 61
28589114 2017
5
Enhanced expression of glucose transporter GLUT3 in tumorigenic HeLa cell hybrids associated with tumor suppressor dysfunction. 61
10336639 1999
6
Localization and characterization of a chromosome 11 tumor suppressor gene using organotypic raft cultures. 61
9067287 1997
7
Carcinoid tumors frequently display genetic abnormalities involving chromosome 11. 61
8784062 1996
8
Genetic heterogeneity of chromosome 11 associated with tumorigenicity in HeLa D98-OR cells. 61
8548745 1995
9
Allelotyping in Wilms tumors identifies a putative third tumor suppressor gene on chromosome 11. 61
7558032 1995
10
Different characteristics of hepatoid and non-hepatoid alpha-fetoprotein-producing gastric carcinomas: an experimental study using xenografted tumors. 61
7519587 1994
11
Putative tumor-suppressor gene on chromosome 11 is important in sporadic endocrine tumor formation. 61
7906100 1994
12
Aldosterone-secreting adrenal adenoma as part of multiple endocrine neoplasia type 1 (MEN1): loss of heterozygosity for polymorphic chromosome 11 deoxyribonucleic acid markers, including the MEN1 locus. 61
1639957 1992
13
Altered neurovirulence of temperature-sensitive vesicular stomatitis virus mutants in a murine model by inoculation of bombesin: a neuropeptide. I. Clinical, virological and pathological observations. 61
2538576 1989
14
Neuropeptide-induced hypothermia and the course of central nervous system disease mediated by temperature-sensitive mutants of vesicular stomatitis virus. 61
2991582 1985
15
Analysis of the defects of temperature-sensitive mutants of vesicular stomatitis virus: intracellular degradation of specific viral proteins. 61
191641 1977
16
Progeny resulting from complementation between mutants of vesicular stomatitis virus. 61
163131 1975
17
Screening procedure for complementation-dependent mutants of vesicular stomatitis virus. 61
163345 1975

Variations for Tumor Suppressor Gene on Chromosome 11

Expression for Tumor Suppressor Gene on Chromosome 11

Search GEO for disease gene expression data for Tumor Suppressor Gene on Chromosome 11.

Pathways for Tumor Suppressor Gene on Chromosome 11

GO Terms for Tumor Suppressor Gene on Chromosome 11

Sources for Tumor Suppressor Gene on Chromosome 11

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....